Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

Dr. Shelagh Coutts receives award for developing new brain scan

Award-winning neurologist Dr. Shelagh Coutts is on the fast track of developing new brain scanning techniques for rapid and effective diagnosis of mini-strokes.

26 Oct 2009

Curriculum to increase science literacy and generate enthusiasm for life sciences among high school students

A new curriculum called The Great Diseases will bring real-world biomedical research to students in three Boston high schools. The result of a collaboration between scientists from Tufts University School of Medicine and teachers from the Boston Public Schools, the curriculum presents current threats to global health through laboratory learning, multimedia, and case-based studies

24 Oct 2009

Cardiac Network announces incubation agreement with Global Private Funding

Cardiac Network, Inc., a leader in advanced mobile medical monitoring, announced today that it has entered into a Business Incubation Services agreement with Global Private Funding, Inc. (Global), a private equity-based lender.

24 Oct 2009

Learn to recognise stroke symptoms and take action: World Stroke Organization

The theme of this year's World Stroke Day on 29th October is "What can I do?". As the World Stroke Organization says, everyone can do something: learn to recognise symptoms and take action, learn to recognise the risk factors and take action.

24 Oct 2009

U.S. District Court rules in favor of Allergan in its patent infringement suit against Exela PharmSci

Allergan, Inc. announced today that the United States District Court for the District of Delaware ruled in favor of Allergan, Inc. in its patent infringement suit against Exela PharmSci, Inc., Exela PharmSci Pvt., Ltd. ("Exela"), Apotex, Inc. and Apotex Corp. ("Apotex") (collectively, the "Defendants") for seeking to market purported generic versions of Allergan’s drugs ALPHAGAN® P (brimonidine tartrate ophthalmic solution) 0.1% and 0.15%. Specifically, after a trial in March of 2009, the Court ruled today that all five patents (U.S. Patent Nos. 6,627,210; 6,641,834; 6,673,337; 6,562,873; and 5,424,078) asserted by Allergan are valid and enforceable, that Apotex's proposed generic versions of ALPHAGAN® P 0.1% and 0.15% infringe each of the five patents, and that Exela's proposed generic version of ALPHAGAN® P 0.15% infringes U.S. Patent No. 6,641,834, which was the only patent asserted against it. Pursuant to the Hatch-Waxman Act, the United States Food and Drug Administration is required to delay approval of Defendants’ proposed generic products until the last to expire of the infringed patents, which is 2022.

24 Oct 2009

Shire announces new pharmacokinetic data of ADHD medication

Shire plc, the global specialty biopharmaceutical company, announced new data about the pharmacokinetics of its Attention-Deficit/Hyperactivity Disorder (ADHD) medication, Vyvanse- (lisdexamfetamine dimesylate) Capsules CII, which showed that Vyvanse provided similar concentrations of its active medication in the blood when administered either intranasally or when administered orally.

23 Oct 2009

Newcardio expert to present clinical validation data of Phase I and TQT studies on ECG

NewCardio, Inc., (OTC Bulletin Board: NWCI) a cardiac diagnostic and services company, today announced that Dr. Sam George, NewCardio's Senior Consultant, will join a distinguished roster of speakers, moderators and panelists at the Cardiac Safety Research Consortium (CSRC) annual meeting in Maryland at the Marriot Bethesda, Pooks Hill location on October 29-30, 2009.

23 Oct 2009

Quality of U.S. health care was virtually stagnant in 2008, says NCQA report

A report released today by the National Committee for Quality Assurance (NCQA) finds that the quality of U.S. health care was virtually stagnant in 2008, a disturbing slowdown after a decade of improvements. The across-the-board trend was seen in care provided to people with private insurance coverage as well as in Medicare and Medicaid.

23 Oct 2009

Boehringer Ingelheim receives European CHMP positive opinion for MICARDIS

Boehringer Ingelheim announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Evaluation Agency (EMEA) has issued a positive opinion for the approval of MICARDIS® (telmisartan) for the reduction of cardiovascular morbidity.

23 Oct 2009

KemPharm commences KP106 Phase 1 clinical trial for ADHD

KemPharm, Inc. today announced that it has commenced a Phase 1 clinical trial in healthy volunteers of its novel prodrug compound, KP106, which is in development for the treatment of attention-deficit hyperactivity disorder (ADHD). KP106, a new chemical entity (NCE) composed of d-amphetamine and a ligand, is the lead investigational candidate from KemPharm’s proprietary ligand activated therapy (LAT) platform, which creates improved versions of FDA-approved drugs. KemPharm began the KP106 program in 2007 and has initiated the Phase 1 clinical trial of this candidate in less than 24 months.

22 Oct 2009

GeneNews announces the publication of a paper in the Journal of Clinical Gastroenterology

GeneNews Limited, a company focused on developing blood-based biomarker tests for the early detection of diseases and personalized health management, today announced the publication of a paper in the Journal of Clinical Gastroenterology. The paper reports data using GeneNews' proprietary Sentinel Principle(R) platform technology to identify complex changes in blood gene expression patterns that were differentially regulated between active and inactive Crohn's disease.

22 Oct 2009

Edwards Lifesciences announces third quarter 2009 results

Edwards Lifesciences Corporation, a world leader in products and technologies to treat advanced cardiovascular disease, today reported net income for the quarter ended September 30, 2009 of $73.5 million, or $1.25 per diluted share, compared to net income of $32.9 million, or $0.56 per diluted share, for the same period in 2008.

22 Oct 2009

CDC urges heart disease patients get vaccinated against the flu each year

Cardiovascular disease was the leading cause of death in Florida in 2005, accounting for approximately 35 percent of all deaths in the state. People with heart disease are at a high risk for serious and potentially life-threatening complications from the flu.

22 Oct 2009

New findings from ADVANCE clinical trial presented

New analyses of the largest-ever clinical trial of patients with type 2 diabetes show that the combination of blood pressure lowering treatment and intensive glucose (blood sugar) control improved patients' vascular condition and resulted in a significant 18 percent reduction in the risk of death from all causes.

22 Oct 2009

iPierian to participate in $3.7 million NIH grant awarded to The Johns Hopkins University

iPierian, Inc., a biopharmaceutical company focused on changing the paradigm of drug discovery and development through the application of cellular reprogramming, today announced that it has been selected to participate in a $3.7 million National Institutes of Health (NIH) Grand Opportunities (GO) grant awarded to The Johns Hopkins University.

22 Oct 2009

King Pharmaceuticals receives FDA complete response letter for CorVue NDA

King Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) issued a complete response letter regarding the New Drug Application (NDA) for CorVue™ (binodenoson) for injection.

21 Oct 2009

New results from ADVANCE provide important insights to reduce diabetes complications

New results from ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation), the largest clinical trial ever performed in patients with type 2 diabetes worldwide, provide important insights into the therapeutic strategy to adopt for efficient and safe blood glucose control aimed at the reduction of severe diabetes complications.

21 Oct 2009

Cheering for your favorite baseball team: Is it hazardous to your health?

A study, led by cardiologist, Dr. Franklin Zimmerman of Columbia University, will use an ambulatory blood pressure monitor (ABPM) to determine whether cheering for your favorite baseball team is hazardous to your health.

21 Oct 2009

Genzyme commences patient enrollment in Genz-112638 phase 3 trials

Genzyme Corporation today announced that the company has begun enrollment in the first of two global, multi-center, phase 3 trials of Genz-112638, a potential new oral therapy for Gaucher disease type 1. The two multi-national, multi-center trials are being conducted to evaluate the safety and efficacy of the small molecule.

21 Oct 2009

Medicaid beneficiaries with disabilities frequently have multiple chronic conditions, says study

Medicaid beneficiaries with disabilities frequently have multiple chronic conditions, and very high rates of psychiatric illness and cardiovascular disease, according to a study released today by the Center for Health Care Strategies.

21 Oct 2009